Efficacy of Acellular Dermal Matrix Allograft (CenoDerm®) with and without Plasma Rich in Growth Factors for Gingival Augmentation: A Clinical Trial

Pasha Ghahari   3/2/2016 12:00:00 AM

Purpose: This study sought to assess the clinical efficacy of CenoDerm® acellular dermal matrix allograft (ADMA) with and without plasma rich in growth factors (PRGF) for gingival augmentation. Methods: This split-mouth double-blind randomized controlled clinical trial was conducted on 10 patients requiring augmentation of keratinized gingiva bilaterally in the mandible (<2mm). The recipient sites were prepared using the conventional free gingival graft (FGG) technique. CenoDerm® was rehydrated with PRGF and saline solution in the test and control groups, respectively. Keratinized tissue (KT) width, gingival thickness, wound healing (healing index by Landry et al), and pain scores according to the visual analog scale (VAS) were evaluated and compared at baseline (preoperatively) and at 2 weeks, 1 month and 3 months, post-operatively. Data were analyzed using the paired t-test and the Wilcoxon signed tank test. Results: At 3 months, KT width was significantly greater in the test compared to the control group (P<0.0001). No significant differences were found between the two groups regarding the healing index at any time point post-operatively. Pain scores were significantly lower in the control group at 1 (P<0.01) and 2 (P<0.009) days; but the difference in this regard at day 3 was not significant. Gingival thickness was not significantly different between the two groups at any time point. Conclusion: Both ADMA+PRGF and ADMA only result in favorable clinical outcomes, but the added benefit of PRGF is not ev¬ident. (This study has been registered in http://www.irct.ir/ and registration code is: IRCT201503261760N38)

Send Message